Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

BACKGROUND: Regorafenib, a multi-kinase inhibitor, is used in the treatment of patients with metastatic colorectal cancer refractory to standard therapy. However, this benefit was limited to 1.4 months improvement in overall survival, with more than half of patients experiencing grade 3 to 4 adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Andrea Li Ann, Lim, Joline Si Jing, Sinha, Arvind, Gopinathan, Anil, Lim, Robert, Tan, Chee-Seng, Soh, Thomas, Venkatesh, Sudhakar, Titin, Christina, Sapari, Nur Sabrina, Lee, Soo-Chin, Yong, Wei-Peng, Tan, David Shao Ping, Pang, Brendan, Wang, Ting-Ting, Zee, Ying-Kiat, Soong, Richie, Trnkova, Zuzana, Lathia, Chetan, Thiery, Jean-Paul, Wilhelm, Scott, Jeffers, Michael, Goh, Boon-Cher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332724/
https://www.ncbi.nlm.nih.gov/pubmed/25889309
http://dx.doi.org/10.1186/s12967-015-0405-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332724/
https://www.ncbi.nlm.nih.gov/pubmed/25889309
http://dx.doi.org/10.1186/s12967-015-0405-4

Ejemplares similares